Chemokines in Alzheimer’s Disease: New Insights Into Prokineticins, Chemokine-Like Proteins
Authors:
Open Access
- 29 May 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 622
Abstract
Alzheimer’s disease is the most common neurodegenerative disorder characterized by the presence of β-amyloid aggregates deposited as senile plaques and by the presence of neurofibrillary tangles of tau protein. To date, there is a broad consensus on the idea that neuroinflammation is one of the most important component in Alzheimer’s disease pathogenesis. Chemokines and their receptors, beside the well-known role in the immune system, are widely expressed in the nervous system, where they play a significant role in the neuroinflammatory processes. Prokineticins are a new family of chemokine-like molecules involved in numerous physiological and pathological processes including immunity, pain, inflammation, and neuroinflammation. Prokineticin 2 (PROK2) and its receptors PKR1 and PKR2 are widely expressed in the central nervous system in both neuronal and glial cells. In Alzheimer’s disease, PROK2 sustains the neuroinflammatory condition and contributes to neurotoxicity, since its expression is strongly upregulated by amyloid-β peptide and reversed by the PKR antagonist PC1. This review aims to summarize the current knowledge on the neurotoxic and/or neuroprotective function of chemokines in Alzheimer’s disease, focusing on the prokineticin system: it represents a new field of investigation that can stimulate the research of innovative pharmacotherapeutic strategies.Keywords
This publication has 98 references indexed in Scilit:
- Alzheimer Mechanisms and Therapeutic StrategiesCell, 2012
- Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1α, suppress amyloid β-induced neurotoxicityToxicology and Applied Pharmacology, 2011
- CXCL8 protects human neurons from amyloid-β-induced neurotoxicity: Relevance to Alzheimer’s diseaseBiochemical and Biophysical Research Communications, 2011
- Regulation of Tau Pathology by the Microglial Fractalkine ReceptorNeuron, 2010
- RANTES upregulation in the Alzheimer's disease brain: A possible neuroprotective roleNeurobiology of Aging, 2010
- Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathwayNeurobiology of Disease, 2009
- Inflammatory changes parallel the early stages of Alzheimer diseaseNeurobiology of Aging, 2007
- Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer diseaseNeurobiology of Disease, 2007
- Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissuesExperimental Cell Research, 2007
- Expression of prokineticins and their receptors in the adult mouse brainJournal of Comparative Neurology, 2006